NCT00000645View on ClinicalTrials.gov

A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

Not specified

Study Completion Date

October 31, 1994

Conditions

HIV Infections

Interventions

DRUG

Hypericin

Trial Locations (3)

10016

NY Univ. HIV/AIDS CRS, New York

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Unknown

University of Minnesota, ACTU, Minneapolis

Sponsors

Collaborators (1)

VIMRx Pharmaceuticals

All Listed Sponsors

collaborator

VIMRx Pharmaceuticals

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000645 - A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes | Biotech Hunter | Biotech Hunter